WO2015023507A3 - Methods for increasing forced expiratory volume in asthmatics using benralizumab - Google Patents

Methods for increasing forced expiratory volume in asthmatics using benralizumab Download PDF

Info

Publication number
WO2015023507A3
WO2015023507A3 PCT/US2014/050119 US2014050119W WO2015023507A3 WO 2015023507 A3 WO2015023507 A3 WO 2015023507A3 US 2014050119 W US2014050119 W US 2014050119W WO 2015023507 A3 WO2015023507 A3 WO 2015023507A3
Authority
WO
WIPO (PCT)
Prior art keywords
benralizumab
methods
asthmatics
expiratory volume
forced expiratory
Prior art date
Application number
PCT/US2014/050119
Other languages
French (fr)
Other versions
WO2015023507A2 (en
WO2015023507A8 (en
Inventor
Christine Ward
Lorin Roskos
Bing Wang
Donald Raible
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP19158446.5A priority Critical patent/EP3520811B1/en
Priority to EP14836725.3A priority patent/EP3033104B1/en
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Priority to LTEP14836725.3T priority patent/LT3033104T/en
Priority to SI201431191T priority patent/SI3033104T1/en
Priority to SG11201600483QA priority patent/SG11201600483QA/en
Priority to BR112016002317A priority patent/BR112016002317A8/en
Priority to CA2917603A priority patent/CA2917603C/en
Priority to ES14836725T priority patent/ES2733602T3/en
Priority to DK14836725.3T priority patent/DK3033104T3/en
Priority to MEP-2019-137A priority patent/ME03403B/en
Priority to CN201480045047.8A priority patent/CN105451769A/en
Priority to EP20208316.8A priority patent/EP3875487A1/en
Priority to PL14836725T priority patent/PL3033104T3/en
Priority to PL19158446T priority patent/PL3520811T3/en
Priority to MX2016001384A priority patent/MX2016001384A/en
Priority to AU2014306959A priority patent/AU2014306959B2/en
Priority to KR1020167006576A priority patent/KR102337599B1/en
Priority to JP2016534615A priority patent/JP6746496B2/en
Priority to RS20190556A priority patent/RS58711B1/en
Priority to RU2016108809A priority patent/RU2703568C2/en
Publication of WO2015023507A2 publication Critical patent/WO2015023507A2/en
Publication of WO2015023507A3 publication Critical patent/WO2015023507A3/en
Publication of WO2015023507A8 publication Critical patent/WO2015023507A8/en
Priority to HK16110776.1A priority patent/HK1222559A1/en
Priority to HRP20190920TT priority patent/HRP20190920T1/en
Priority to CY20191100700T priority patent/CY1122033T1/en
Priority to AU2020201277A priority patent/AU2020201277A1/en
Priority to CY20211100261T priority patent/CY1124399T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)

Abstract

Provided herein is are methods of increasing forced expiratory volume in one second (FEV1) in an asthma patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
PCT/US2014/050119 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab WO2015023507A2 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
MX2016001384A MX2016001384A (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab.
PL19158446T PL3520811T3 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
LTEP14836725.3T LT3033104T (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
EP14836725.3A EP3033104B1 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
SG11201600483QA SG11201600483QA (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
BR112016002317A BR112016002317A8 (en) 2013-08-12 2014-08-07 USE OF BENRALIZUMAB OR AN ANTIGEN-BINDING FRAGMENT THEREOF TO INCREASE FORCED EXPIRATORY VOLUME IN ASTHMATICS AND BENRALIZUMAB OR AN ANTIGEN-BINDING FRAGMENT THEREOF FOR USE TO INCREASE FORCED EXPIRATORY VOLUME IN ASTHMATICS
CA2917603A CA2917603C (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
ES14836725T ES2733602T3 (en) 2013-08-12 2014-08-07 Methods to increase forced expiratory volume in asthmatic patients using benralizumab
DK14836725.3T DK3033104T3 (en) 2013-08-12 2014-08-07 PROCEDURES FOR INCREASING FOREQUARTERED ECOSPIRATORY VOLUME IN ASTMATICS BY USING BENRALIZUMAB
MEP-2019-137A ME03403B (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
AU2014306959A AU2014306959B2 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
EP20208316.8A EP3875487A1 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
PL14836725T PL3033104T3 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
EP19158446.5A EP3520811B1 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
SI201431191T SI3033104T1 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
CN201480045047.8A CN105451769A (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
KR1020167006576A KR102337599B1 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
JP2016534615A JP6746496B2 (en) 2013-08-12 2014-08-07 How to use Benralitumab to increase forced vital capacity in asthmatics
RS20190556A RS58711B1 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
RU2016108809A RU2703568C2 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatic patients using benralizumab
HK16110776.1A HK1222559A1 (en) 2013-08-12 2016-09-12 Methods for increasing forced expiratory volume in asthmatics using benralizumab
HRP20190920TT HRP20190920T1 (en) 2013-08-12 2019-05-17 Methods for increasing forced expiratory volume in asthmatics using benralizumab
CY20191100700T CY1122033T1 (en) 2013-08-12 2019-07-03 METHODS OF INCREASING EXHAUST VOLUME IN ASTHMATICS USING BENRALIZUMAB
AU2020201277A AU2020201277A1 (en) 2013-08-12 2020-02-21 Methods for increasing forced expiratory volume in asthmatics using benralizumab
CY20211100261T CY1124399T1 (en) 2013-08-12 2021-03-24 METHODS OF INCREASING VOLUME IN ASTHMATICS USING BENRALIZUMAB

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
US61/864,948 2013-08-12

Publications (3)

Publication Number Publication Date
WO2015023507A2 WO2015023507A2 (en) 2015-02-19
WO2015023507A3 true WO2015023507A3 (en) 2015-04-09
WO2015023507A8 WO2015023507A8 (en) 2015-09-24

Family

ID=52448838

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/050119 WO2015023507A2 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Country Status (25)

Country Link
US (1) US9441046B2 (en)
EP (3) EP3520811B1 (en)
JP (3) JP6746496B2 (en)
KR (1) KR102337599B1 (en)
CN (2) CN111588849A (en)
AU (2) AU2014306959B2 (en)
BR (1) BR112016002317A8 (en)
CA (1) CA2917603C (en)
CY (2) CY1122033T1 (en)
DK (2) DK3033104T3 (en)
ES (2) ES2733602T3 (en)
HK (2) HK1222559A1 (en)
HR (2) HRP20190920T1 (en)
HU (2) HUE043497T2 (en)
LT (2) LT3520811T (en)
ME (1) ME03403B (en)
MX (2) MX2016001384A (en)
PL (2) PL3520811T3 (en)
PT (2) PT3033104T (en)
RS (2) RS61565B1 (en)
RU (1) RU2703568C2 (en)
SG (1) SG11201600483QA (en)
SI (2) SI3033104T1 (en)
TR (1) TR201907907T4 (en)
WO (1) WO2015023507A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3988114A1 (en) * 2013-08-12 2022-04-27 Astrazeneca AB Methods for improving asthma symptoms using benralizumab
HUE042607T2 (en) * 2013-08-12 2019-07-29 Astrazeneca Ab Methods for reducing exacerbation rates of asthma using benralizumab
BR112016008082A2 (en) * 2013-10-15 2017-10-17 Medimmune Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
KR102238065B1 (en) * 2013-10-24 2021-04-07 아스트라제네카 아베 Stable, aqueous antibody formulations
TW202110479A (en) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 Methods for treating chronic obstructive pulmonary disease in an enhanced patient population using benralizumab
TW202214692A (en) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 Methods for treating severe asthma in patients with nasal polyposis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120156194A1 (en) * 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
US20120328606A1 (en) * 2011-05-18 2012-12-27 Medimmune, Llc Methods Of Diagnosing And Treating Pulmonary Diseases Or Disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE283926T1 (en) 1995-09-11 2004-12-15 Kyowa Hakko Kogyo Kk ANTIBODIES AGAINST THE ALPHA CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
JPWO2005035583A1 (en) 2003-10-08 2007-11-22 協和醗酵工業株式会社 Antibody composition that specifically binds to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
MX2009012341A (en) 2007-05-14 2010-02-17 Medimmune Llc Methods of reducing eosinophil levels.
RU2383345C1 (en) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Method of treating patients with bronchial asthma
CN102544908B (en) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 Electric coupler component and pin connector
JP2014533246A (en) * 2011-11-01 2014-12-11 メディミューン，エルエルシー How to reduce the frequency and severity of acute exacerbations of asthma
HUE042607T2 (en) * 2013-08-12 2019-07-29 Astrazeneca Ab Methods for reducing exacerbation rates of asthma using benralizumab
EP3988114A1 (en) * 2013-08-12 2022-04-27 Astrazeneca AB Methods for improving asthma symptoms using benralizumab

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120156194A1 (en) * 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
US20120328606A1 (en) * 2011-05-18 2012-12-27 Medimmune, Llc Methods Of Diagnosing And Treating Pulmonary Diseases Or Disorders

Also Published As

Publication number Publication date
US9441046B2 (en) 2016-09-13
DK3520811T3 (en) 2021-03-22
EP3520811B1 (en) 2020-12-30
CY1124399T1 (en) 2022-07-22
AU2014306959B2 (en) 2019-11-21
HUE043497T2 (en) 2019-08-28
US20150044203A1 (en) 2015-02-12
CA2917603C (en) 2023-05-16
HRP20190920T1 (en) 2019-07-12
CN105451769A (en) 2016-03-30
RS58711B1 (en) 2019-06-28
ME03403B (en) 2020-01-20
TR201907907T4 (en) 2019-06-21
LT3520811T (en) 2021-03-25
HK1222559A1 (en) 2017-07-07
HK1225300A1 (en) 2017-09-08
EP3033104A4 (en) 2017-03-22
EP3875487A1 (en) 2021-09-08
ES2733602T3 (en) 2019-12-02
PL3520811T3 (en) 2021-08-02
AU2014306959A1 (en) 2016-02-04
RU2016108809A3 (en) 2018-06-18
BR112016002317A8 (en) 2018-06-12
SI3033104T1 (en) 2019-06-28
JP2016527325A (en) 2016-09-08
PL3033104T3 (en) 2019-09-30
MX2016001384A (en) 2016-08-03
PT3520811T (en) 2021-03-15
BR112016002317A2 (en) 2017-12-12
CN111588849A (en) 2020-08-28
CY1122033T1 (en) 2020-10-14
RU2016108809A (en) 2017-09-18
DK3033104T3 (en) 2019-06-17
EP3033104A2 (en) 2016-06-22
HUE053627T2 (en) 2021-07-28
WO2015023507A2 (en) 2015-02-19
HRP20210406T1 (en) 2021-04-30
AU2020201277A1 (en) 2020-03-12
PT3033104T (en) 2019-06-27
ES2866426T3 (en) 2021-10-19
LT3033104T (en) 2019-06-25
CA2917603A1 (en) 2015-02-19
EP3520811A1 (en) 2019-08-07
MX2021003826A (en) 2021-05-27
SI3520811T1 (en) 2021-04-30
JP2020125304A (en) 2020-08-20
SG11201600483QA (en) 2016-02-26
WO2015023507A8 (en) 2015-09-24
RU2703568C2 (en) 2019-10-21
RS61565B1 (en) 2021-04-29
KR20160043049A (en) 2016-04-20
KR102337599B1 (en) 2021-12-10
JP2022120010A (en) 2022-08-17
EP3033104B1 (en) 2019-04-03
JP6746496B2 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
MX2021003826A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab.
WO2012062925A3 (en) Compounds and methods for treating pain
MY195289A (en) Anti IL-36R Antibodies
WO2016014974A3 (en) Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2014028777A3 (en) Methods of treating a tauopathy
WO2014158811A8 (en) Newcastle disease viruses and uses thereof
DK3791896T3 (en) COMBINATION THERAPY WITH ANTIBODIES AGAINST CLAUDIN 18.2 FOR THE TREATMENT OF CANCER
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2010149798A3 (en) Use of polyols for enhancing the cooling effect of a cooling substance and cooling mixtures having an enhanced cooling effect
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
WO2015023504A8 (en) Methods for reducing exacerbation rates of asthma using benralizumab
WO2012158437A3 (en) Cannula apparatus and ventricular assist systems using the cannula apparatus
UA117032C2 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
WO2015023508A8 (en) Methods for improving asthma symptoms using benralizumab
NZ616048A (en) Administration of iloprost as aerosol bolus
WO2014152754A3 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
WO2015009591A3 (en) Treatment for melanoma
WO2012119780A3 (en) Novel lipids and novel phospholipids structures
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2019013468A (en) Methods for treating chronic obstructive pulmonary disease using benralizumab.
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
WO2014115033A3 (en) A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications
WO2014026013A3 (en) Methods for maintaining or improving health, well-being and/or a physiological function in a subject

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480045047.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14836725

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2917603

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/001384

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2014306959

Country of ref document: AU

Date of ref document: 20140807

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016534615

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016002317

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2014836725

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20167006576

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016108809

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14836725

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112016002317

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112016002317

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160202